title: After the treated mole.
authors.forename: Armin
authors.initials: A
authors.lastname: Rashidi
authors.forename: Elaine M
authors.initials: EM
authors.lastname: Maherus
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D003609:Dactinomycin / Q000009:adverse effects / Q000627:therapeutic use; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006828:Hydatidiform Mole / Q000188:drug therapy; D016130:Immunophenotyping; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000175:diagnosis; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000175:diagnosis; D011247:Pregnancy; D014327:Trophoblasts / Q000473:pathology; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D003609:Dactinomycin; D014750:Vincristine; D005047:Etoposide; D003520:Cyclophosphamide; D008727:Methotrexate